Compare KRKR & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRKR | LABT |
|---|---|---|
| Founded | 2010 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 4.6M |
| IPO Year | 2019 | 2026 |
| Metric | KRKR | LABT |
|---|---|---|
| Price | $3.00 | $2.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.0K | ★ 2.0M |
| Earning Date | 03-17-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $1.66 |
| 52 Week High | $21.36 | $6.85 |
| Indicator | KRKR | LABT |
|---|---|---|
| Relative Strength Index (RSI) | 57.27 | 42.88 |
| Support Level | $2.84 | $2.10 |
| Resistance Level | $3.25 | $2.50 |
| Average True Range (ATR) | 0.22 | 0.26 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 71.21 | 57.14 |
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in the PRC.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.